Blaine Labs Recalls Wound Care Gel Products Due to Microbial Contamination

Blaine Labs, Inc. has initiated a voluntary nationwide recall of three lot numbers of Wound Care Gel products (1 oz. and 3 oz., 0.1% Benzalkonium Chloride) due to microbial contamination. The Santa Fe Springs, California manufacturer announced the recall on April 7, 2026, removing affected lots from distribution channels. Wholesale drug distributors holding inventory of these products must immediately quarantine stock and coordinate returns with Blaine Labs.

Regulatory Framework

The recall falls under FDA's authority over drug products under the Federal Food, Drug, and Cosmetic Act. Benzalkonium Chloride wound care gels are classified as over-the-counter (OTC) topical antiseptics regulated as drug products under 21 CFR Part 200. Microbial contamination in antiseptic products presents a direct health risk: a product intended to prevent infection becomes a vector for it.

FDA classifies recalls by severity. Microbial contamination typically triggers a Class II recall (products that may cause temporary or medically reversible adverse health consequences) or Class I recall (products that could cause serious adverse health consequences or death). The classification for this Blaine Labs recall has not yet been published in FDA's Enforcement Reports database as of April 8, 2026.

Under 21 CFR 7.46, manufacturers conducting voluntary recalls must notify FDA's District Recall Coordinator and provide a recall strategy. Distributors are responsible for identifying affected inventory, segregating product, and executing the recall strategy within their facilities and downstream customer base.

Affected Products and Lot Details

The recall covers three specific lot numbers:

• Lot 250901: 1 oz. Wound Care Gel (0.1% Benzalkonium Chloride)
• Lot 250902: 1 oz. Wound Care Gel (0.1% Benzalkonium Chloride)
• Lot 260301: 3 oz. Wound Care Gel (0.1% Benzalkonium Chloride)

Blaine Labs has not disclosed distribution dates, expiration dates, or the specific microbial species detected. These details typically appear in FDA's Enforcement Report when the recall is formally classified.

Distributors holding inventory should verify lot numbers immediately. Product distributed to retail pharmacies, institutional purchasers, or secondary wholesalers must be traced using DSCSA transaction records. Under 21 USC 360eee-1, wholesale distributors are required to maintain Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) records for six years. These records enable rapid identification of affected product locations during recall execution.

Impact on Wholesale Distributors and 3PLs

Wholesale drug distributors must execute three immediate actions:

1. Inventory quarantine: Physically segregate all units matching recalled lot numbers. Mark as "Do Not Ship" in the warehouse management system. This prevents further distribution while recall processing occurs.

1. Customer notification: Contact all customers who received affected lots. Provide lot numbers, recall reason, and return instructions. DSCSA transaction records identify the exact trading partners who received each serialized unit or homogenous case.

1. Return coordination: Arrange credit processing and reverse logistics with Blaine Labs. Typical recall processes involve returning product to the manufacturer or approved destruction following state board of pharmacy and DEA requirements (if applicable).

Third-party logistics providers (3PLs) storing product on behalf of wholesale distributors or manufacturers must follow client-specific recall procedures. 3PLs do not own title to inventory but are responsible for accurate lot traceability and physical segregation. Current Good Manufacturing Practice (cGMP) requirements under 21 CFR Part 211.204 mandate written procedures for handling recalled products.

Compliance and Documentation Requirements

State boards of pharmacy may require distributors to file incident reports documenting recall participation. California Business and Professions Code Section 4164 requires licensed wholesalers to establish recall policies and maintain recall records. Distributors operating in multiple states must comply with jurisdiction-specific reporting requirements.

Audit trails documenting recall execution become critical during state or FDA inspections. Distributors should retain:

• Customer notification records (emails, certified mail receipts)
• Inventory segregation logs showing quarantine dates
• Return documentation (credit memos, destruction certificates)
• DSCSA transaction records proving downstream traceability

Failure to execute recalls effectively can result in state board enforcement actions, including license suspension or civil penalties.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain logistics providers across 51 jurisdictions. Of these entities, 73 (5.7%) have at least one FDA recall on record in our database. The Blaine Labs recall adds to the universe of enforcement actions that compliance teams must monitor when qualifying and auditing trading partners.

Recall execution capability correlates with overall compliance posture. Entities with active FDA registration, current state licensure, and documented quality systems respond more effectively to recalls. In ColdChainCheck's scoring model, recalls are a negative compliance signal but not disqualifying—what matters is how the entity documents and executes the recall response. Distributors with established recall procedures, documented lot traceability, and transparent customer notification processes maintain higher compliance scores despite isolated recall events.

The average compliance score across tracked entities is 51/100, placing most distributors in the "Fair" tier (919 entities). Only 28 entities score in the "Excellent" range (76-100 points), reflecting complete, verified compliance signals across all six data dimensions: state licensure, NABP accreditation, FDA registration, DEA registration, recall history, and warning letter history. For QA teams evaluating trading partners who may have received Blaine Labs products, the compliance score provides a starting point for due diligence—not a substitute for verifying recall participation directly.

Practical Steps for Compliance Teams

• Query trading partner records: If your organization sources OTC topical products, cross-reference your approved distributor list against ColdChainCheck's directory. Check whether any trading partners have recent recall history that suggests gaps in lot traceability or customer notification processes. Entities with multiple recalls within 24 months warrant additional scrutiny during vendor re-qualification.

• Verify DSCSA readiness: Distributors unable to produce Transaction Information, Transaction History, and Transaction Statement records cannot execute recalls effectively. Use ColdChainCheck's FDA registration status indicator to confirm that distributors maintain active establishment registration—a baseline requirement for drug product handling under 21 CFR Part 207. Review DSCSA compliance requirements to understand how transaction record integrity supports recall execution.

• Monitor state board enforcement: ColdChainCheck tracks state pharmacy board licensing data for 1,275 entities across 51 jurisdictions. During recall events, state boards may issue disciplinary actions against distributors that fail to execute recalls promptly. Check the directory for suspended or expired licenses—a common outcome when recall participation is inadequate.

• Document your own recall response: If your facility received Blaine Labs Wound Care Gel, document quarantine actions, customer notifications, and return processing. This documentation demonstrates compliance during state board or FDA inspections. ColdChainCheck's compliance guides provide templates for recall procedure documentation at /guides.

ColdChainCheck continuously updates recall data as FDA publishes Enforcement Reports. The Blaine Labs recall will appear in affected entities' compliance profiles once FDA assigns a classification and publishes distribution details. Compliance teams can monitor recall trends and enforcement patterns across the wholesale distributor landscape using the directory's filtering tools.

Disclaimer: This article provides informational content based on publicly available FDA recall data as of April 8, 2026. It is not legal or regulatory advice. Verify all compliance obligations with your legal counsel and the relevant regulatory authorities.